Skip to main content
Search
Search
Toggle navigation
About Terumo India
Col 1
About Terumo India
Col 2
Dear Stakeholders
Who We Are
At a Glance
Terumo Group Identity
Col 3
Leadership Team
History
Terumo's Purpose
Response to COVID-19
Business Overview
Col 1
Business Overview
Col 2
TIS Division (Terumo Interventional Systems)
Cardiovascular Division (Terumo Cardiovascular)
Vascular Graft Division (Terumo Aortic)
Col 3
Life Care Solutions Division
Pharmaceutical Solutions Division
Sustainability
col 1
Sustainability
col 2
CSR Initiatives
CSR Policy & Committee
col 3
Award & Recognition
Creating a Diverse and Inclusive Workplace
Technology
col 1
Technology Overview
col 2
Basic Information
col 3
Stories - Our Technologies
News
Col 1-4
News
Col 2-2
Col 2-4
December 12, 2022
Financial
Notification of Completion of Acquisition and Cancellation of Own Shares (PDF 115.79 KB) (Acquisition of the company's own shares pursuant to item 2 of Article 165 of the Corporate Law concerning the provisions of the articles of incorporation)
Col 3-4
December 8, 2022
Corporate
Ultimaster Drug Eluting Stent family (Terumo) first stent to receive the mention 1-month DAPT in the reimbursement conditions in France
Col 4-4
December 06, 2022
Corporate
Terumo Announces Launch of Drug-Device Combination Product Co-Developed with Kyowa Kirin
Global Network
Col 1
Global Network
Col 2
Japan
North America
South America
Col 3
EMEA
Greater China
Asia and Pacific
Home
Terumo Website Feed
Terumo Website Feed
February 14, 2023
Terumo Blood and Cell Technologies’ IMUGARD Platelet Pooling Set Cleared by FDA
March 2, 2023
Terumo to Further Drive DE&I by Establishing Focus Areas to Commit Globally
December 12, 2022
Notification of Completion of Acquisition and Cancellation of Own Shares
March 7, 2023
Terumo Prospective Registry Reinforces Safety, Efficacy and Efficiency of Radial Access in Visceral Interventions (R.A.V.I.) in Embolization Procedures
December 8, 2022
Ultimaster Drug Eluting Stent family (Terumo) first stent to receive the mention 1-month DAPT in the reimbursement conditions in France
April 12, 2023
Notice Concerning Partial Amendments to the Articles of Incorporation
December 6, 2022
Terumo Announces Launch of Drug-Device Combination Product Co-Developed with Kyowa Kirin
April 24, 2023
Terumo Group’s Targets for Greenhouse Gas Reduction Approved by the SBT Initiative as 1.5°C Aligned
December 2, 2022
Notification Regarding Status of Acquisition of the Company's Own Shares
April 21, 2023
Terumo Aortic Announces First Implant of Innovative Custom-made Thoracoabdominal Hybrid Device in North America
December 1, 2022
Terumo Announces All Dexcom G6 CGM System Users on Insulin Therapy to be Covered by Insurance in Japan
April 26, 2023
Ultimaster Nagomi™ MDR certification and launch of large-scale post-market study investigating the new coronary stent system in complex PCI
January 18, 2023
First Patient Treated and Enrolled in Terumo Medical Corporation’s Osprey Iliac IDE Clinical Trial
May 5, 2023
Terumo Aortic Announces FDA Approval of Dissection and Transection Indication Expansion for the RELAY®Pro Stent-graft System in the United States
January 25, 2023
Terumo and Siemens Healthineers India collaborate to strengthen cardiac care in India
May 15, 2023
Terumo to Construct a New Manufacturing Facility at its Kofu Factory for the Medical Care Solutions Company
January 26, 2023
Terumo Group to Establish the Sustainability Committee
May 15, 2023
Terumo Appoints the Candidates for Directors
February 9, 2023
Terumo to Revise Performance Evaluation System for Executive Officers
May 25, 2023
Terumo Blood and Cell Technologies Optimizing Cell Therapy Production Through Industry’s First Apheresis Training for Cell Therapy Manufacturers
February 9, 2023
Terumo Announces Change of Executive Officers
February 9, 2023
Notice Concerning Revision of the Year-end Dividend Forecast for Fiscal Year Ending March 31, 2023 (Dividend Increase)
February 9, 2023
Notice Concerning Revision of the Full-Year Financial Guidance for Fiscal Year Ending March 31, 2023 (FY2022)
February 23, 2023
Terumo Blood and Cell Technologies Presents First Quantum Flex Data for Multiple Size Bioreactors Showing Rapid T-Cell Expansion to Numbers Equivalent to a Therapeutic Dose
February 22, 2023
Terumo India Partners with Siemens Healthineers to Introduce First of Its Kind Programme for Cathlab Directors in Collaboration with ISB Executive Education
Contact
Us
Top